Edwards Lifesciences (EW) Receivables - Other (2009 - 2026)

Edwards Lifesciences has reported Receivables - Other for 18 years, with the latest figure at $185.3 million in Q2 2026.

• On a quarterly basis, Receivables - Other fell 9.87% year-over-year to $185.3 million in Q2 2026; TTM through Jun 2026 was $185.3 million, a 9.87% decrease from a year earlier, with the FY2025 full-year figure at $252.5 million, up 113.44% from the prior year.
• Receivables - Other was $185.3 million for Q2 2026 at Edwards Lifesciences, down from $197.3 million in the prior quarter.
• The five-year high for Receivables - Other was $252.5 million in Q4 2025, with the low at $42.8 million in Q2 2022.
• Average Receivables - Other over 5 years is $104.8 million, with a median of $62.4 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: Receivables - Other tumbled 35.78% in 2022, then soared 266.49% in 2025.
• Over 5 years, Receivables - Other stood at $56.1 million in 2022, then grew by 0.89% to $56.6 million in 2023, then surged by 109.01% to $118.3 million in 2024, then jumped by 113.44% to $252.5 million in 2025, then decreased by 26.61% to $185.3 million in 2026.
• The last three Receivables - Other figures came in at $185.3 million (Q2 2026), $197.3 million (Q1 2026), and $252.5 million (Q4 2025), per Business Quant data.